CN103316286A - Application of medicine in treatment stent post-operation angiogenesis promoting medicines - Google Patents
Application of medicine in treatment stent post-operation angiogenesis promoting medicines Download PDFInfo
- Publication number
- CN103316286A CN103316286A CN2013101931260A CN201310193126A CN103316286A CN 103316286 A CN103316286 A CN 103316286A CN 2013101931260 A CN2013101931260 A CN 2013101931260A CN 201310193126 A CN201310193126 A CN 201310193126A CN 103316286 A CN103316286 A CN 103316286A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- coronary
- treatment
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an application of a medicine in the preparation of coronary heart disease treatment stent post-operation myocardial ischemia disease medicines. The medicine is prepared by using 8-12 parts by weight of Radix Curcumae Aromaticae, 13-17 parts by weight of Radix Codonopsis and 8-12 parts by weight of Rhizoma Polygonati Odorati. The medicine is prepared through using pure traditional Chinese medicines, has a wide expectant range and has no toxic side effects. The medicine has the advantages of less raw material components, abundant and easily available raw materials, low price, simple preparation technology and suitableness for the popularized use. The above traditional Chinese medicine has the functions of coronary artery expansion, platelet aggregation resistance, thrombosis resistance, blood viscosity reduction, microcirculation improvement, and angiogenesis and endothelial restoration promotion, and has a short treatment course and a substantial effect when the medicine is used for treating myocardial ischemia.
Description
Technical field
The present invention relates to a kind of application, specifically, is about the application in the angiogenesis promoting medicine behind the treatment stenting of a kind of medicine.
Background technology
Coronary atherosclerotic heart disease (coronary atherosclerotic heart disease) is called for short coronary heart disease, be because coronary artery is functional or organic disease causes the cardiac damage due to the imbalance between coronary blood supply and the myocardium demand, claim again ischemic heart desease (ischemic heart disease).
For the treatment of coronary heart disease, main principle is to improve blood supply coronarius and alleviate myocardial ischemia and oxygen consumption, simultaneously treatment and the atherosis development of prevention of arterial.Wherein, the coronary heart disease stenting is one of therapeutic method of surgery of coronary heart disease, its ultimate principle is that foley's tube is inserted in the narrow blood vessel by vascular puncture, external with the sacculus pressurized expansion, strut narrow blood vessel wall, make lesion vessels recover unimpeded, 1-2 place coronary stricture and put support and easily can select interventional therapy.But find clinically, some coronary heart disease coronary artery bracket postoperative patient persons are the problem of coronary stricture, myocardial ischemia still, for this class patient, increase coronary arterial tree or collateral circulation, the confession of recovery ischemic myocardium blood, also be very important to improving patient's symptom and prognosis.
Summary of the invention
The objective of the invention is provides a kind of application for deficiency of the prior art.
For achieving the above object, the technical scheme that the present invention takes is: a kind of medicine is the application in the angiogenesis promoting medicine behind preparation treatment coronary heart disease stenting, and described medicine is to be made by the crude drug of following weight portion: Radix Curcumae 8-12 part, Radix Codonopsis 13-17 part, Rhizoma Polygonati Odorati 8-12 part.
Described medicine is to be made by the crude drug of following weight portion: 10 parts of Radix Curcumaes, 13 parts of Radix Codonopsis, 10 parts of Rhizoma Polygonati Odorati.
The invention has the advantages that: medicine of the present invention is made by pure Chinese medicine, the medicine wide ranges of suiting the medicine to the illness, no side effects.Medicine material component of the present invention is few, and abundant raw materials is easy to get, low price, and preparation technology is simple, is fit to promote the use of.Chinese medicine of the present invention has coronary artery dilating, antiplatelet aggregation, and antithrombotic forms, and reduces blood viscosity, improves microcirculation angiogenesis promoting and endothelium repair function, treatment myocardial ischemia short treating period, effect is remarkable.
The specific embodiment
The below elaborates to the specific embodiment provided by the invention.
Embodiment 1
Chinese drug preparation (one)
Get 10 parts of 10 parts of Chinese medicine Radix Curcumaes, 15 parts of Radix Codonopsis, Rhizoma Polygonati Odorati and put and decoct in the container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 2
Chinese drug preparation (two)
Get 8 parts of Chinese medicine Radix Curcumaes, 13 parts of Radix Codonopsis, 8 parts of Rhizoma Polygonati Odorati, put in the decoction container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 3
Chinese drug preparation (three)
Get 12 parts of Chinese medicine Radix Curcumaes, 17 parts of Radix Codonopsis, 12 parts of Rhizoma Polygonati Odorati, put in the decoction container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 4
Chinese drug preparation (four)
Get 8 parts of Chinese medicine Radix Curcumaes, 15 parts of Radix Codonopsis, 12 parts of Rhizoma Polygonati Odorati, put in the decoction container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 5
Chinese drug preparation (five)
Get 12 parts of Chinese medicine Radix Curcumaes, 15 parts of Radix Codonopsis, 8 parts of Rhizoma Polygonati Odorati, put in the decoction container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 6
Chinese drug preparation (six)
Get 8 parts of Chinese medicine Radix Curcumaes, 15 parts of Radix Codonopsis, 10 parts of Rhizoma Polygonati Odorati, put in the decoction container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 7
Chinese drug preparation (seven)
Get 12 parts of Chinese medicine Radix Curcumaes, 15 parts of Radix Codonopsis, 8 parts of Rhizoma Polygonati Odorati, put in the decoction container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 8
Chinese drug preparation (eight)
Get 10 parts of Chinese medicine Radix Curcumaes, 13 parts of Radix Codonopsis, 10 parts of Rhizoma Polygonati Odorati, put in the decoction container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 9
Chinese drug preparation (nine)
Get 11 parts of Chinese medicine Radix Curcumaes, 16 parts of Radix Codonopsis, 9 parts of Rhizoma Polygonati Odorati, put in the decoction container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.The water that medicinal residues add 4 times of amounts continues to decoct, and boils 20 min, filters.Merge filtrate twice, in water-bath, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml, cool off the sterilization medicine bottle of packing into, put 4 ℃ of refrigerators for subsequent use.
Embodiment 10
The randomized controlled trial of myocardial ischemia behind the pharmaceutical intervention coronary heart disease stenting of the present invention
1 clinical data and method
1.1 case is selected and grouping
All cases derives from January, 2005 to 2007 year JIUYUE Hospitals of Shanghai cardiological patients.Selected 150 routine patients with coronary heart disease mostly are acute myocardial infarction and angina pectoris altogether.Male's 90 examples wherein, women's 60 examples, age 35-75 year, average (67 ± 6) year, be divided into treatment group 1, treatment group 2, treatment group 3 and matched group by selected standard completely random method.Inclusive criteria: the equal underwent coronary radiography of patient is made a definite diagnosis coronary heart disease, and in age 35-75 year, male or female meets following: 1. belong to acute scheming infarction or stable angina pectoris or unstable angina pectoris.2. there are two or narrow or inaccessible more than two Major Coronary arteries and veins 60%-99% through coronary angiography, have at least one to be fit to the row percutaneous transluminal coronary stent implantation, and owing to also have at least an arteria coronaria blood vessel still to exist 〉=narrow or inaccessible more than 75% behind a variety of causes Stent.3. the lesion vessels diameter is 2.5-4.0mm, and does not go in the past coronary artery balloon dilatation (PTCA).4. implanting coronary artery bracket is non-bracket for eluting medicament, and stent length is not more than 25mm.5. without aspirin, heparin, Plavix taboo person.Exclusion standard: 1. be associated with diabetes.2. severe cardiac functional defect, cardiac function is IV person.3. long pathological changes is greater than 25mm person.4. acute upper respiratory tract infection.5. malignant change.6. bifurcated lesions person.7. coronary artery bypass (CABG) person.
1.2 Therapeutic Method
Four groups of patients all use fat regulation medicine according to the state of an illness, anticoagulant, and the platelet receptor blocker, nitrate esters, beta-Blocking agent, the calcium ion blocker, ACEI, the medicines such as ARB etc. are as Primary Care.Treatment group 1, treatment group 2 and treatment group 3 respectively behind Stent 24h internal therapy group give the medicine of embodiment 1, embodiment 8 and embodiment 9 described treatment coronary heart disease, a 150ml, every day three times, oral.Matched group only adopts Primary Care.Cycle is 6 months.
1.3 observation index and method
1.3.1 arteria coronaria side shoot integration
Adopt blood vessel numeral inspection shadow (DSA) to detect the degree of arteria coronaria collateral circulation, the arteria coronaria side shoot is according to international Cohen-Rentrop method method (Isaac Pouriati, MD, Carey Kimmelstiel, MD, William Rand, PhD.Statin use isassociated with enhanced collateralizaton of severely diseased coronary arteries. America heart journal, November 2003 Volume146, Number5.876-81.).0=is without any collateral blood vessels, and 1=has collateral blood vessels to be poured but do not arrive the visceral pericardium part, and the 2=collateral blood vessels partly is filled into visceral pericardium, and the 3=collateral blood vessels is filled into visceral pericardium fully.Then point out higher integration if any a plurality of side shoots, then select a higher blood vessel of integration to calculate if any vascular lesion many places, many places side shoot.
1.3.2 stent restenosis
According to the standard shadowgraph technique respectively before PTCA, support implant after, row coronary angiography after six months, in arteria coronaria, measure respectively the lumen of vessels internal diameter behind the injection nitroglycerin.
1.3.3 ejection fraction (EF)
Use the two dimensional echocardiogram machine to adopt and revise Simpson formula measurement EF.
1.4 date processing
Adopt SPSS 11.0 statistical softwares statistics, carry out the variance analysis of repeated measure, t check and χ
2Check.With P＜0.05 for statistical significance is arranged.
2 results
The variation of four groups for the treatment of front and back arteria coronaria collateral circulation integrations is as shown in table 1, as can be seen from Table 1, four groups all have less collateral circulation even do not have collateral circulation when selected, but treatment group 1, treatment group 2 and treatment group 3 are after through 6 months treatment, more side shoot has appearred, P＜0.01 is compared with matched group and to be had utmost point significant difference.
The variation of arteria coronaria collateral circulation integration before and after four groups of treatments of table 1
| Process | n | Before the treatment | 6 months |
| Treatment group 1 | 30 | 0.11±0.1 | 2.01±0.1**## |
| Treatment group 2 | 30 | 0.11±0.11 | 2.02±0.15**## |
| Treatment group 3 | 30 | 0.12±0.12 | 2.12±0.12**## |
| Matched group | 31 | 0.12±0.12 | 1.40±0.11 |
Annotate: compare with matched group: * * P＜0.01; When selected relatively: ##P＜0.01.
Four groups of variations for the treatment of front and back tube chamber and stent restenosis are as shown in table 2, as can be seen from Table 2, aspect minimum lumen diameter and luminal stenosis percentage rate, treatment group 1, treatment group 2, treatment group 3 and the more equal no difference of science of statistics of matched group.Total clinical restenosis rate is 11%, and wherein treatment group 1 has 3 examples, and treatment group 2 has 3 examples, and treatment group 3 has 2 examples, and matched group has 3 examples.
The variation of tube chamber and stent restenosis before and after four groups of treatments of table 2
Annotate: compare with matched group: * P＜0.05.
The variation of four groups for the treatment of front and back EF is as shown in table 3, as can be seen from Table 3, treatment group 1, treatment group 2 and treatment group 3 are after 6 months, and ejection fraction obviously improves, treatment group 1, treatment group 2, treatment group 3 and matched group and relatively front with treatment, P＜0.05 has remarkable significant difference.
The variation of EF before and after four groups of treatments of table 3
| Process | n | Before the treatment | 6 months |
| Treatment group 1 | 30 | 0.46±0.14 | 0.51±0.21*# |
| Treatment group 2 | 30 | 0.46±0.20 | 0.51±0.22*# |
| Treatment group 3 | 30 | 0.45±0.19 | 0.51±0.26*# |
| Matched group | 31 | 0.45±0.21 | 0.44±0.24 |
Annotate: compare with matched group: * P＜0.05; When selected relatively: #P＜0.05.
The GCP principle is strictly followed in this research, carries out contrived experiment according to completely random, contrast, single blind design method.Under study for action routine blood test, routine urinalysis, hepatic and renal function etc. are observed the safety of medicine of the present invention, the result does not have untoward reaction to occur, first proved the safety of this medicine.Secondly, result of study confirms that medicine of the present invention can significantly improve collateral circulation and the ejection fraction of patients with coronary heart disease, and then improves myocardial ischemia, significantly improves cardiac function.
Claims (2)
1. medicine application in the angiogenesis promoting medicine behind preparation treatment coronary heart disease stenting, described medicine is to be made by the crude drug of following weight portion: Radix Curcumae 8-12 part, Radix Codonopsis 13-17 part, Rhizoma Polygonati Odorati 8-12 part.
2. require as requested 1 described application, described medicine is to be made by the crude drug of following weight portion: 10 parts of Radix Curcumaes, 13 parts of Radix Codonopsis, 10 parts of Rhizoma Polygonati Odorati.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101931260A CN103316286A (en) | 2013-05-23 | 2013-05-23 | Application of medicine in treatment stent post-operation angiogenesis promoting medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101931260A CN103316286A (en) | 2013-05-23 | 2013-05-23 | Application of medicine in treatment stent post-operation angiogenesis promoting medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103316286A true CN103316286A (en) | 2013-09-25 |
Family
ID=49185519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101931260A Pending CN103316286A (en) | 2013-05-23 | 2013-05-23 | Application of medicine in treatment stent post-operation angiogenesis promoting medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103316286A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1393257A (en) * | 2001-06-26 | 2003-01-29 | 邓大勇 | Medicine for treating cardiovascular disease |
| CN101559203A (en) * | 2009-06-03 | 2009-10-21 | 李兴华 | Chinese medicament preparation for treating angina pectoris |
| CN102228596A (en) * | 2011-06-30 | 2011-11-02 | 云南云药科技股份有限公司 | Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris |
-
2013
- 2013-05-23 CN CN2013101931260A patent/CN103316286A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1393257A (en) * | 2001-06-26 | 2003-01-29 | 邓大勇 | Medicine for treating cardiovascular disease |
| CN101559203A (en) * | 2009-06-03 | 2009-10-21 | 李兴华 | Chinese medicament preparation for treating angina pectoris |
| CN102228596A (en) * | 2011-06-30 | 2011-11-02 | 云南云药科技股份有限公司 | Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris |
Non-Patent Citations (1)
| Title |
|---|
| 第六次全国中西医结合心血管会学术会议论文汇编: "冠心一号对急性心肌梗塞后心室重构干预的临床观察", 《第六次全国中西医结合心血管会学术会议论文汇编》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524421B (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN209137002U (en) | A kind of medicinal balloon | |
| CN101647856B (en) | Medicine for treating coronary heart disease and preparation method thereof | |
| CN103381260A (en) | Application of traditional Chinese medicinal composition in treating coronary heart disease | |
| CN103316286A (en) | Application of medicine in treatment stent post-operation angiogenesis promoting medicines | |
| CN103316287A (en) | Application of traditional Chinese medicinal composition in preparation of treatment stent post-operation angiogenesis promoting medicines | |
| CN103381262A (en) | Traditional Chinese medicinal composition for treating myocardial ischemia of coronary heart disease | |
| CN103381261A (en) | Application of traditional Chinese medicinal composition in treating myocardial ischemia disease | |
| CN103316288A (en) | Application of medicine in myocardial ischemia disease treatment | |
| CN103405714A (en) | Medicine for treatment of coronary atherosclerotic heart disease myocardial ischemia | |
| CN103272174A (en) | Application of drug in treatment of coronary heart disease | |
| CN103566292A (en) | Application of traditional Chinese medicine composition in preparation of medicine for increasing collateral circulation | |
| CN103263638A (en) | Application of medicine to medicine capable of increasing collateral circulation | |
| CN102188699A (en) | Pharmaceutical composition for treating atherosclerosis, and preparation method and application thereof | |
| CN102416034B (en) | Medicament for treating myocardial ischemia in coronary heart disease and application thereof | |
| CN101439101B (en) | Chinese medicinal composition for treating restenosis after coronary intervention and preparation method thereof | |
| CN105287755A (en) | Traditional Chinese medicinal composition for treating sepsis myocardial dysfunction | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN101766674B (en) | Medicament composition for preventing and controlling restenosis after intracoronary stent implantation | |
| CN101744938B (en) | Pharmaceutical composition and preparation method thereof | |
| Quan et al. | Acute left heart failure caused by Takayasu arteritis: a case report and literature review | |
| CN101675946B (en) | Application of a traditional Chinese medicine in preparing a medicine for reducing inflammatory reaction after PCI | |
| CN104524421B (en) | A kind of Chinese medicine for treating miocardial infarction postoperative restenosis | |
| CN103505488A (en) | Traditional Chinese medicine composition of pseudo-ginseng and sea-buckthorn and preparation method of composition | |
| Ji et al. | The intervention of nano-targeted drugs & angioplastryin treatment and prevention of vascular restenosis and its influence on monocyte chemotactic protein-1 in lower extremity angiopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130925 |